Shifting trends in bacteriology and antimicrobial resistance among gastrointestinal fistula patients in China: an eight-year review in a tertiary-care hospital

Table 2 Antimicrobial resistance of Escherichia coli isolates to the tested antibiotics

Resistance rate (%)
Isolate/Antibiotics	2008–2011	2012–2015	Total	P for Trend Test
All Escherichia coli
AMK	7.78	14.16	11.33	0.154
AMP	97.92	96.49	97.14	0.537
SAM	81.97	87.93	85.88	0.279
TZP	23.47	25.00	24.30	0.795
CZO	92.55	91.30	91.87	0.742
CAZ	81.82	69.83	75.35	0.042
FEP	75.51	62.07	68.22	0.035
IPM	14.29	25.86	20.56	0.037
CIP	90.16	79.13	82.95	0.064
ESBL+
AMK	6.78	12.33	9.85	0.287
AMP	100.00	100.00	100.00	–
SAM	77.78	93.15	88.07	0.020
TZP	20.31	6.85	13.14	0.020
SXT	84.21	73.61	77.27	0.207
CZO	100.00	100.00	100.00	–
CAZ	89.23	68.49	78.26	0.003
FEP	81.25	60.27	70.07	0.007
IPM	12.31	8.22	10.14	0.427
CIP	86.11	80.82	82.57	0.494
ESBL-
AMK	6.67	16.22	13.46	0.361
AMP	88.24	89.74	89.29	0.867
SAM	77.78	77.50	77.55	0.986
ZP	35.29	57.50	50.88	0.125
SXT	88.89	67.50	71.43	0.199
CZO	58.82	74.36	69.64	0.245
CTT	28.57	70.00	63.83	0.035
CAZ	52.94	70.00	64.91	0.217
FEP	52.94	62.50	59.65	0.501
IPM	43.75	57.50	53.57	0.351
CIP	88.89	77.50	79.59	0.444
Not all tested antibiotics are listed

AMK Amikacin, AMP Ampicillin, SAM Ampicillin/Sulbactam, CAZ Ceftazidime, efepime, CTT Cefotetan, CZO Cefazolin, IPM Imipenem, TZP Piperacillin-Tazobactam, CIP Ciprofloxacin
Data in boldface reflected p values < 0.05

ISSN: 1471-2334